Cat. No.: HY-12686

5Z-7-Oxozeaenol

(Synonyms: FR148083; L783279; LL-Z 1640-2)

32 Cited Publications

Customer Review

Based on 32 publication(s) in Google Scholar

5Z-7-Oxozeaenol is a natural anti-protozoan compound from fungal origin, acting as a potent irreversible and selective inhibitor of TAK1 and VEGF-R2, with IC₅₀s of 8 nM and 52 nM, respectively.

For research use only. We do not sell to patients.

Purity: 99.30%
CAS No.: 253863-19-3
Formula: C₁₉H₂₂O₇
Molecular Weight:362.37

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

5Z-7-Oxozeaenol Chemical Structure

CAS No.: 253863-19-3

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (32)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[2]

TAK1

8.1 nM (IC₅₀)

MEK1

411 nM (IC₅₀)

VEGFR-2

52 nM (IC₅₀)

VEGFR-3

110 nM (IC₅₀)

FLT3

170 nM (IC₅₀)

PDGFR-β

340 nM (IC₅₀)

B-RAF VE

6300 nM (IC₅₀)

SRC

6600 nM (IC₅₀)

All MAP3K Isoforms :

All VEGFR Isoforms :

All Antibiotic Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
ASPC1	IC₅₀	6020 nM Compound: 5Z7	Antiproliferative activity against human AsPC1 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human AsPC1 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay	[PMID: 28038940]
BaF3	IC₅₀	12 nM Compound: 5Z7	Antiproliferative activity against mouse BA/F3 cells harboring KRAS G12D mutant after 72 hrs in presence of IL-3 by CellTiter-Glo assay Antiproliferative activity against mouse BA/F3 cells harboring KRAS G12D mutant after 72 hrs in presence of IL-3 by CellTiter-Glo assay	[PMID: 28038940]
BaF3	IC₅₀	4 nM Compound: 5Z7	Antiproliferative activity against mouse BA/F3 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay Antiproliferative activity against mouse BA/F3 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay	[PMID: 28038940]
HCT-15	EC₅₀	2 nM Compound: 1	Cytotoxicity against TNFalpha-induced human HCT-15 cells assessed as reduction in cell viability preincubated for 2 hrs followed by TNFalpha stimulation and measured after 72 hrs by celltiter-glo assay Cytotoxicity against TNFalpha-induced human HCT-15 cells assessed as reduction in cell viability preincubated for 2 hrs followed by TNFalpha stimulation and measured after 72 hrs by celltiter-glo assay	[PMID: 33859795]
HeLa	IC₅₀	0.25 μM Compound: 5	Inhibition of NFkappa p65 isolated from nuclear extract of human HeLa cells by ELISA Inhibition of NFkappa p65 isolated from nuclear extract of human HeLa cells by ELISA	[PMID: 21513293]
HT-29	IC₅₀	3.6 μM Compound: 5	Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay	[PMID: 21513293]
MCF7	IC₅₀	3.8 μM Compound: 5	Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 21513293]
MDA-MB-435	IC₅₀	3.3 μM Compound: 5	Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTS assay Cytotoxicity against human MDA-MB-435 cells after 72 hrs by MTS assay	[PMID: 21513293]
NCI-H23	IC₅₀	1 μM Compound: 5Z7	Antiproliferative activity against human NCI-H23 cells harboring KRAS G12C mutant after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human NCI-H23 cells harboring KRAS G12C mutant after 72 hrs by CellTiter-Glo assay	[PMID: 28038940]
NCI-H460	IC₅₀	1.2 μM Compound: 5	Cytotoxicity against human H460 cells after 72 hrs by MTS assay Cytotoxicity against human H460 cells after 72 hrs by MTS assay	[PMID: 21513293]
PANC-1	IC₅₀	2500 nM Compound: 5Z7	Antiproliferative activity against human PANC1 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human PANC1 cells harboring KRAS G12D mutant after 72 hrs by CellTiter-Glo assay	[PMID: 28038940]
SF-268	IC₅₀	5.1 μM Compound: 5	Cytotoxicity against human SF268 cells after 72 hrs by MTS assay Cytotoxicity against human SF268 cells after 72 hrs by MTS assay	[PMID: 21513293]
Sf9	IC₅₀	8.1 nM Compound: 1	Inhibition of TAK1 (unknown origin) expressed in sf9 cells assessed as 32P level incorporation into myelin basic protein incubated for 5 mins at 30 degC by immunoprecipitation method Inhibition of TAK1 (unknown origin) expressed in sf9 cells assessed as 32P level incorporation into myelin basic protein incubated for 5 mins at 30 degC by immunoprecipitation method	[PMID: 26481152]
SK-CO-1	IC₅₀	250 nM Compound: 5Z7	Antiproliferative activity against human SKCO1 cells harboring KRAS G12V mutant after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human SKCO1 cells harboring KRAS G12V mutant after 72 hrs by CellTiter-Glo assay	[PMID: 28038940]
SW-620	IC₅₀	2540 nM Compound: 5Z7	Antiproliferative activity against human SW620 cells harboring KRAS G12V mutant after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human SW620 cells harboring KRAS G12V mutant after 72 hrs by CellTiter-Glo assay	[PMID: 28038940]
THP-1	IC₅₀	11 nM Compound: 1, f152A1	Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha production by PLAP reporter assay Antiinflammatory activity in human THP1 cells assessed as inhibition of LPS-induced TNFalpha production by PLAP reporter assay	[PMID: 19783437]

In Vitro

5Z-7-Oxozeaenol is a potent irreversible and selective inhibitor of transforming growth factor (TGF)-β-activated kinase 1 (TAK1, IC₅₀, 8.1 nM), less active on MEK1 (IC₅₀, 411 nM). 5Z-7-Oxozeaenol prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase^[1]. 5Z-7-Oxozeaenol is also an inhibitor of VEGF-R2, with an IC₅₀ of 52 nM. 5Z-7-Oxozeaenol has inhibitory activity against VEGF-R3, FLT3, PDGFR-β, B-RAF VE and SRC, with IC₅₀s of 110, 170, 340, 6300 and 6600 nM, respectively^[2]. 5Z-7-Oxozeaenol inhibits JNK/p38 paythway, but it is not a direct inhibitor and is signal specific. 5Z-7-Oxozeaenol suppresses the PMA-induced AP-1 activity almost to the basal level in the KT cells, but has no effects on IL-1-induced NF-kB activity in the KK cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 253863-19-3
Appearance Solid
Molecular Weight 362.37
Formula C₁₉H₂₂O₇
Color White to off-white
SMILES

O=C(O[C@@H](C)C/C=C\1)C2=C(O)C=C(OC)C=C2/C=C/C[C@H](O)[C@H](O)C1=O
Synonyms

FR148083; L783279; LL-Z 1640-2
Structure Classification
- Phenols
- Monophenols
- Others
Initial Source
- Microorganisms
Cochliobolus lunatus
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (32)

All Histological Imaging/StainingIn Vivo Efficacy StudyWBCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Nature

Necroptosis blockade prevents lung injury in severe influenza. [Abstract]

2024 Apr;628(8009):835-843. PMID: 38600381
Autophagy

TRIM21-mediated ubiquitination of SQSTM1/p62 abolishes its Ser403 phosphorylation and enhances palmitic acid cytotoxicity. [Abstract]

2025 Jan;21(1):178-190. PMID: 39172027
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Sci Adv

TBK1 and IKKε prevent premature cell death by limiting the activity of both RIPK1 and NLRP3 death pathways. [Abstract]

2025 Mar 7;11(10):eadq1047. PMID: 40053580
Sci Adv

Tgfβ signaling stimulates glycolysis to promote the genesis of synovial joint interzone in developing mouse embryonic limbs. [Abstract]

2025 Jan 10;11(2):eadq4991. PMID: 39772668
Cell Death Dis

GCN5-mediated regulation of pathological cardiac hypertrophy via activation of the TAK1-JNK/p38 signaling pathway. [Abstract]

2022 Apr 30;13(4):421. PMID: 35490166

5Z-7-Oxozeaenol purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Apr 30;13(4):421. [Abstract]

5Z-7-oxozeaenol（iTAK1, 5 mg/kg; i.p.; once daily for 4 weeks)-induced histological changes in heart sections stained with H&E and WGA to analyze heart and cardiomyocyte size, respectively. (n = 6-7 mice/group).

5Z-7-Oxozeaenol purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Apr 30;13(4):421. [Abstract]

Effects of 5Z-7-oxozeaenol（iTAK1, 5 mg/kg; i.p.; once daily for 4 weeks) on EF, FS, and LVESd values in GCN5-overexpressing mice and control mice after sham or TAC surgery (n = 6–7 mice/group).
J Immunother Cancer

Chemotherapy induces an IL1β-dependent neutrophil recruitment and activation that promote chemoresistance in metastatic ovarian cancer. [Abstract]

2026 Jun 3;14(6):e014253. PMID: 42236112
J Exp Med

Adenosine metabolic clearance maintains liver homeostasis by licensing arginine methylation of RIPK1. [Abstract]

2026 Jan 5;223(1):e20250603. PMID: 41081715

5Z-7-Oxozeaenol purchased from MedChemExpress. Usage Cited in: J Exp Med. 2026 Jan 5;223(1):e20250603. [Abstract]

The cells were stimulated by Flag-TNFα (100 ng/ml) after pretreatment of 5Z-7-Oxozeaenol (5z7, 500 nM) for 30 min. After stimulation for indicated periods, complex I was immunoprecipitated with Flag antibody. Relative levels of TNFR1, p-RIPK1 (S166), RIPK1, TRADD in complex I or whole-cell lysates were measured with immunoblotting.

5Z-7-Oxozeaenol purchased from MedChemExpress. Usage Cited in: J Exp Med. 2026 Jan 5;223(1):e20250603. [Abstract]

Ripk1^−/− MEFs were reconstituted with WT or R606K mutant Flag-RIPK1 by lentivirus. The cells were subsequently treated with 5Z-7-Oxozeaenol (5z7, 500 nM)/TNFα (10 ng/mL) for the indicated time in the presence or absence of Nec-1s (10 μM). Cell death was measured by the SYTOX Green positivity assay.
Acta Pharmacol Sin

Baicalin inhibits PANoptosis by blocking mitochondrial Z-DNA formation and ZBP1-PANoptosome assembly in macrophages. [Abstract]

2025 Feb;46(2):430-447. PMID: 39223367
Cell Death Discov

Silencing TAK1 reduces MAPKs-MMP2/9 expression to reduce inflammation-driven neurohistological disruption post spinal cord injury. [Abstract]

2021 May 8;7(1):96. PMID: 33966042
Oncogene

Targeting VPS4 elicits STING-driven anti-tumor immunity to suppress rhabdomyosarcoma growth. [Abstract]

2026 Jun;45(23):2211-2224. PMID: 42032367
Cell Rep

Macrophage-specific PHGDH protects against MAFLD by suppressing TAK1. [Abstract]

2025 Mar 16;44(3):115426. PMID: 40096087
Cell Rep

Unveiling the physiological impact of ESCRT-dependent autophagosome closure by targeting the VPS37A ubiquitin E2 variant-like domain. [Abstract]

2024 Nov 27;43(12):115016. PMID: 39607828
Int Immunopharmacol

Luteolin mitigates inflammatory organ injury by targeting XIAP to block PANoptosis and mitochondrial dysfunction. [Abstract]

2026 Mar 15:173:116271. PMID: 41637826
Int Immunopharmacol

Scutellarin inhibits inflammatory PANoptosis by diminishing mitochondrial ROS generation and blocking PANoptosome formation. [Abstract]

2024 Sep 30:139:112710. PMID: 39029229
Int Immunopharmacol

Liensinine alleviates high fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) through suppressing oxidative stress and inflammation via regulating TAK1/AMPK signaling. [Abstract]

2022 Mar:104:108306. PMID: 34999396
J Nutr Biochem

Therapeutic potential of wogonoside in hypertension-induced cardiac injury: Targeting apoptosis and MAPK signaling pathway. [Abstract]

2026 Sep:155:110383. PMID: 41990999
J Inflamm Res

Integrated Multi-Omics Analysis Reveals IRF1-Driven Microglial PANoptosis via ZBP1 in Spinal Cord Injury. [Abstract]

2026 Mar 16:19:574990. PMID: 41867458
FASEB J

Betaine-homocysteine methyltransferase attenuates liver ischemia-reperfusion injury by targeting TAK1. [Abstract]

2025 Jan 31;39(2):e70349. PMID: 39854060
J Virol

African swine fever virus I177L induces host inflammatory responses by facilitating the TRAF6-TAK1 axis and NLRP3 inflammasome assembly. [Abstract]

2025 Apr 15;99(4):e0208024. PMID: 40135893
Viruses

Inducible miR-150 Inhibits Porcine Reproductive and Respiratory Syndrome Virus Replication by Targeting Viral Genome and Suppressor of Cytokine Signaling 1. [Abstract]

2022 Jul 7;14(7):1485. PMID: 35891465
Cardiovasc Drugs Ther

TAK1-AMPK Pathway in Macrophages Regulates Hypothyroid Atherosclerosis. [Abstract]

2021 Jun;35(3):599-612. PMID: 32495070
Exp Eye Res

Senescent retinal pigment epithelial cells promote angiogenesis in choroidal neovascularization via the TAK1/p38 MAPK pathway. [Abstract]

2025 Feb:251:110232. PMID: 39778673
Brain Behav

5Z-7-Oxozaenol attenuates cuprizone-induced demyelination in mice through microglia polarization regulation. [Abstract]

2024 Apr;14(4):e3487. PMID: 38648385
Vet Microbiol

Highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) induces IL-6 production through TAK-1/JNK/AP-1 and TAK-1/NF-κB signaling pathways. [Abstract]

2021 May:256:109061. PMID: 33836390
Neurosci Lett

Deficiency of CD93 exacerbates inflammation-induced activation and migration of BV2 microglia by regulating the TAK1/NF-κB pathway. [Abstract]

2022 Nov 20:791:136914. PMID: 36270452

5Z-7-Oxozeaenol purchased from MedChemExpress. Usage Cited in: Neurosci Lett. 2022 Nov 20:791:136914. [Abstract]

5Z-7-oxozeaenol (10 nM) significantly inhibits LPS-induced high expression of NF-κB and TAK1 in microglial.
Infect Microbes Dis

2023 Jul 24.
bioRxiv

2026 Jan 25.
SSRN

2025 Dec 2.
McGill University

2023 Dec.
Research Square Preprint

2024 Apr 15.
Research Square Print

2023 Mar 14.

Solvent & Solubility

In Vitro:

DMSO : 30 mg/mL (82.79 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7596 mL

13.7981 mL

27.5961 mL

5 mM

0.5519 mL

2.7596 mL

5.5192 mL

10 mM

0.2760 mL

1.3798 mL

2.7596 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Kinase Assay^[1]

For screening TAK1 inhibitors, insect expression vectors for TAK1 and TAB1 are co-infected into Sf9 cells. After 2 days of incubation, cell lysates are immunoprecipitated with anti-TAK1 antibody (M-17). The immunoprecipitates are incubated with various compounds (5Z-7-Oxozeaenol, etc.) and subsequently incubated with 2 μg of myelin basic protein and 10 μCi of [γ-³²P]ATP (3,000 Ci/mmol) in 10 μL of the kinase buffer containing 10 mM HEPES (pH 7.4), 1 mM dithiothreitol, 5 mM MgCl₂ at 30°C for 5 min. Samples are separated by 10% SDS-PAGE, and ³²P incorporated into myelin basic protein is quantified with a bioimage analyzer. The catalytic activity of MEK1 is determined by activation of ERK2 to phosphorylate dure. The catalytic activity of MEKK1 is measured with 2 μg of myelin basic protein as a substrate in the kinase buffer. For subsequent kinase assays, immunoprecipitates are incubated with 5 μCi of [γ-³²P]ATP (3,000 Ci/mmol) and 1 μg of bacterially expressed MKK6 or GST-IκBα-(1-72) in 10 μL of the kinase buffer at 25°C for 2 min. Samples are separated by 10% SDS-PAGE and visualized by autoradiography^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ninomiya-Tsuji J, et al. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem. 2003 May 16;278(20):18485-90. [Content Brief]

[2]. Dakas PY, et al. Modular synthesis of radicicol A and related resorcylic acid lactones, potent kinase inhibitors. Angew Chem Int Ed Engl. 2007;46(36):6899-902. [Content Brief]

[3]. Takehana K, et al. A radicicol-related macrocyclic nonaketide compound, antibiotic LL-Z1640-2, inhibits the JNK/p38 pathways in signal-specific manner. Biochem Biophys Res Commun. 1999 Apr 2;257(1):19-23. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7596 mL	13.7981 mL	27.5961 mL	68.9903 mL
	5 mM	0.5519 mL	2.7596 mL	5.5192 mL	13.7981 mL
	10 mM	0.2760 mL	1.3798 mL	2.7596 mL	6.8990 mL
	15 mM	0.1840 mL	0.9199 mL	1.8397 mL	4.5994 mL
	20 mM	0.1380 mL	0.6899 mL	1.3798 mL	3.4495 mL
	25 mM	0.1104 mL	0.5519 mL	1.1038 mL	2.7596 mL
	30 mM	0.0920 mL	0.4599 mL	0.9199 mL	2.2997 mL
	40 mM	0.0690 mL	0.3450 mL	0.6899 mL	1.7248 mL
	50 mM	0.0552 mL	0.2760 mL	0.5519 mL	1.3798 mL
	60 mM	0.0460 mL	0.2300 mL	0.4599 mL	1.1498 mL
	80 mM	0.0345 mL	0.1725 mL	0.3450 mL	0.8624 mL

Keywords

5Z-7-Oxozeaenol

32 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

5Z-7-Oxozeaenol

Macrocyclic Compound Library

MCE Bioactive Compound Library

Natural Product Library Plus

Publications Citing Use of MedChemExpress (MCE) 5Z-7-Oxozeaenol

All MAP3K Isoforms

All VEGFR Isoforms

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (32)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

5Z-7-Oxozeaenol

Macrocyclic Compound Library

MCE Bioactive Compound Library

Natural Product Library Plus

Publications Citing Use of MedChemExpress (MCE) 5Z-7-Oxozeaenol

All MAP3K Isoforms

All VEGFR Isoforms

All Antibiotic Isoforms

Biological Activity

Chemical Information

Publications (32)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

5Z-7-Oxozeaenol Related Classifications

HY-12686 Related Classifications